3/14/2025

Janusmed fosterpåverkan

Janusmed fosterpåverkan – Elvanse Vuxen

Janusmed fosterpåverkan tillhandahåller bedömningar av eventuella risker för fostret, när en gravid kvinna använder olika läkemedel. Observera att texterna är generella, och att en bedömning måste göras i varje enskilt fall. Om du inte är medicinskt utbildad, läs först vår information för patienter och allmänhet.

För att komma till startsidan för Janusmed fosterpåverkan och för att göra sökningar klicka här.

Tillbaka till index
2 2
2 2

Lisdexamfetamin

Lisdexamfetamin

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. Cohen JM, Srinivas C, Furu K, Cesta CE, Reutfors J, Karlstad Ø. Prevalence trends and individual patterns of ADHD medication use in pregnancy in Norway and Sweden, 2010-2019. Eur J Clin Pharmacol. 2023;79(1):173-180.

  2. Nörby U, Winbladh B, Källén K. Perinatal Outcomes After Treatment With ADHD Medication During Pregnancy. Pediatrics. 2017 Nov 10. pii: e20170747.

  3. Diav-Citrin O, Shechtman S, Arnon J, Wajnberg R, Borisch C, Beck E et al. Methylphenidate in Pregnancy: A Multicenter, Prospective, Comparative, Observational Study. J Clin Psychiatry. 2016;77:1176-1181.

  4. Pottegård A, Hallas J, Andersen JT, Løkkegaard EC, Dideriksen D, Aagaard L et al. First-trimester exposure to methylphenidate: a population-based cohort study. J Clin Psychiatry. 2014;75:e88-93.

  5. Bro SP, Kjaersgaard MI, Parner ET, Sørensen MJ, Olsen J, Bech BH et al. Adverse pregnancy outcomes after exposure to methylphenidate or atomoxetine during pregnancy. Clin Epidemiol. 2015;7:139-47.

  6. Dideriksen D, Pottegård A, Hallas J, Aagaard L, Damkier P. First trimester in utero exposure to methylphenidate. Basic Clin Pharmacol Toxicol. 2013;112:73-6.

  7. Huybrechts KF, Bröms G, Christensen LB, Einarsdóttir K, Engeland A, Furu K et al. Association Between Methylphenidate and Amphetamine Use in Pregnancy and Risk of Congenital Malformations: A Cohort Study From the International Pregnancy Safety Study Consortium. JAMA Psychiatry. JAMA Psychiatry. 2017 Dec 13. doi: 10.1001/jamapsychiatry.2017.3644. [Epub ahead of print].

  8. Camacho X, Zoega H, Gomes T, Schaffer AL, Henry D, Pearson SA et al. The association between psychostimulant use in pregnancy and adverse maternal and neonatal outcomes: results from a distributed analysis in two similar jurisdictions. Int J Epidemiol. 2023;52(1):190-202.

  9. Källén B, Borg N, Reis M. The use of central nervous system active drugs during pregnancy. Pharmaceuticals (Basel). 2013;6:1221-86.

  10. Kolding L, Ehrenstein V, Pedersen L, Sandager P, Petersen OB, Uldbjerg N et al. Associations Between ADHD Medication Use in Pregnancy and Severe Malformations Based on Prenatal and Postnatal Diagnoses: A Danish Registry-Based Study. J Clin Psychiatry. 2021;82(1):0.

  11. Anderson KN, Dutton AC, Broussard CS, Farr SL, Lind JN, Visser SN et al. ADHD Medication Use During Pregnancy and Risk for Selected Birth Defects: National Birth Defects Prevention Study, 1998-2011. J Atten Disord. 2020;24(3):479-489.

  12. Cohen JM, Hernández-Díaz S, Bateman BT, Park Y, Desai RJ, Gray KJ, Patorno E, Mogun H, Huybrechts KF. Placental Complications Associated With Psychostimulant Use in Pregnancy. Obstet Gynecol. 2017 Nov 3. doi: 10.1097/AOG.0000000000002362.

  13. Haervig KB, Mortensen LH, Hansen AV, Strandberg-Larsen K. Use of ADHD medication during pregnancy from 1999 to 2010: a Danish register-based study. Pharmacoepidemiol Drug Saf. 2014;23:526-33.

  14. Suarez EA, Bateman BT, Hernandez-Diaz S, Straub L, McDougle CJ, Wisner KL, Gray KJ, Pennell PB, Lester B, Zhu Y, Mogun H, Huybrechts KF. Prescription Stimulant Use During Pregnancy and Risk of Neurodevelopmental Disorders in Children. JAMA Psychiatry. 2024 Jan 24:e235073. doi: 10.1001/jamapsychiatry.2023.5073. Epub ahead of print. PMID: 38265792; PMCID: PMC10809143.

  15. Bang Madsen K, Robakis TK, Liu X, Momen N, Larsson H, Dreier JW et al. In utero exposure to ADHD medication and long-term offspring outcomes. Mol Psychiatry. 2023;0(0):0.

  16. Hutson PH, Pennick M, Secker R. Preclinical pharmacokinetics, pharmacology and toxicology of lisdexamfetamine: A novel d-amphetamine pro-drug. Neuropharmacology. 2014;Mar:1.

  17. Poulton AS, Armstrong B, Nanan RK. Perinatal Outcomes of Women Diagnosed with Attention-Deficit/Hyperactivity Disorder: An Australian Population-Based Cohort Study. CNS Drugs. 2018;32(4):377-386.

  18. Eriksson M, Jonsson B, Steneroth G et al. Amphetamine abuse during pregnancy: environmental factors and outcome after 14-15 years. Scand J Public Health 2000;28:154-7.

  19. Eriksson M, Jonsson B, Zetterström R. Children of mothers abusing amphetamine: head circumference during infancy and psychosocial development until 14 years of age. Acta Paediat 2000;89:1474-78.

  1. Cohen JM, Srinivas C, Furu K, Cesta CE, Reutfors J, Karlstad Ø. Prevalence trends and individual patterns of ADHD medication use in pregnancy in Norway and Sweden, 2010-2019. Eur J Clin Pharmacol. 2023;79(1):173-180.
  2. Nörby U, Winbladh B, Källén K. Perinatal Outcomes After Treatment With ADHD Medication During Pregnancy. Pediatrics. 2017 Nov 10. pii: e20170747.
  3. Diav-Citrin O, Shechtman S, Arnon J, Wajnberg R, Borisch C, Beck E et al. Methylphenidate in Pregnancy: A Multicenter, Prospective, Comparative, Observational Study. J Clin Psychiatry. 2016;77:1176-1181.
  4. Pottegård A, Hallas J, Andersen JT, Løkkegaard EC, Dideriksen D, Aagaard L et al. First-trimester exposure to methylphenidate: a population-based cohort study. J Clin Psychiatry. 2014;75:e88-93.
  5. Bro SP, Kjaersgaard MI, Parner ET, Sørensen MJ, Olsen J, Bech BH et al. Adverse pregnancy outcomes after exposure to methylphenidate or atomoxetine during pregnancy. Clin Epidemiol. 2015;7:139-47.
  6. Dideriksen D, Pottegård A, Hallas J, Aagaard L, Damkier P. First trimester in utero exposure to methylphenidate. Basic Clin Pharmacol Toxicol. 2013;112:73-6.
  7. Huybrechts KF, Bröms G, Christensen LB, Einarsdóttir K, Engeland A, Furu K et al. Association Between Methylphenidate and Amphetamine Use in Pregnancy and Risk of Congenital Malformations: A Cohort Study From the International Pregnancy Safety Study Consortium. JAMA Psychiatry. JAMA Psychiatry. 2017 Dec 13. doi: 10.1001/jamapsychiatry.2017.3644. [Epub ahead of print].
  8. Camacho X, Zoega H, Gomes T, Schaffer AL, Henry D, Pearson SA et al. The association between psychostimulant use in pregnancy and adverse maternal and neonatal outcomes: results from a distributed analysis in two similar jurisdictions. Int J Epidemiol. 2023;52(1):190-202.
  9. Källén B, Borg N, Reis M. The use of central nervous system active drugs during pregnancy. Pharmaceuticals (Basel). 2013;6:1221-86.
  10. Kolding L, Ehrenstein V, Pedersen L, Sandager P, Petersen OB, Uldbjerg N et al. Associations Between ADHD Medication Use in Pregnancy and Severe Malformations Based on Prenatal and Postnatal Diagnoses: A Danish Registry-Based Study. J Clin Psychiatry. 2021;82(1):0.
  11. Anderson KN, Dutton AC, Broussard CS, Farr SL, Lind JN, Visser SN et al. ADHD Medication Use During Pregnancy and Risk for Selected Birth Defects: National Birth Defects Prevention Study, 1998-2011. J Atten Disord. 2020;24(3):479-489.
  12. Cohen JM, Hernández-Díaz S, Bateman BT, Park Y, Desai RJ, Gray KJ, Patorno E, Mogun H, Huybrechts KF. Placental Complications Associated With Psychostimulant Use in Pregnancy. Obstet Gynecol. 2017 Nov 3. doi: 10.1097/AOG.0000000000002362.
  13. Haervig KB, Mortensen LH, Hansen AV, Strandberg-Larsen K. Use of ADHD medication during pregnancy from 1999 to 2010: a Danish register-based study. Pharmacoepidemiol Drug Saf. 2014;23:526-33.
  14. Suarez EA, Bateman BT, Hernandez-Diaz S, Straub L, McDougle CJ, Wisner KL, Gray KJ, Pennell PB, Lester B, Zhu Y, Mogun H, Huybrechts KF. Prescription Stimulant Use During Pregnancy and Risk of Neurodevelopmental Disorders in Children. JAMA Psychiatry. 2024 Jan 24:e235073. doi: 10.1001/jamapsychiatry.2023.5073. Epub ahead of print. PMID: 38265792; PMCID: PMC10809143.
  15. Bang Madsen K, Robakis TK, Liu X, Momen N, Larsson H, Dreier JW et al. In utero exposure to ADHD medication and long-term offspring outcomes. Mol Psychiatry. 2023;0(0):0.
  16. Hutson PH, Pennick M, Secker R. Preclinical pharmacokinetics, pharmacology and toxicology of lisdexamfetamine: A novel d-amphetamine pro-drug. Neuropharmacology. 2014;Mar:1.
  17. Poulton AS, Armstrong B, Nanan RK. Perinatal Outcomes of Women Diagnosed with Attention-Deficit/Hyperactivity Disorder: An Australian Population-Based Cohort Study. CNS Drugs. 2018;32(4):377-386.
  18. Eriksson M, Jonsson B, Steneroth G et al. Amphetamine abuse during pregnancy: environmental factors and outcome after 14-15 years. Scand J Public Health 2000;28:154-7.
  19. Eriksson M, Jonsson B, Zetterström R. Children of mothers abusing amphetamine: head circumference during infancy and psychosocial development until 14 years of age. Acta Paediat 2000;89:1474-78.